Access to cataract surgery in public and private health systems ...

GIL AL, ET AL.
Short duration treatment with triamcinolone was effective and
safe in this sample of patients with type 2 DM. It is likely that to
prolong the beneficial effects of triamcinolone, intensified glycemic
and blood pressure control should be part of the treatment of diffuse
diabetic maculopathy. The alternative of using laser after intravitreal
triamcinolone is still controversial (16,17) and it must be evaluated in
well-designed clinical trials. The possibility of association with other
pharmaceuticals used intravitreally, such as the anti-VEGFs (pegaptanib
sodium), may also be a therapeutic alternative to improve the
results of the treatment of diabetic maculopathy (25) .
During the study macular thickness diminished in the triamcinolone
group, especially in the first month of treatment. At 3 and 6
months there was no difference. Macular thickness did not change
during the study in the laser group. In the study sample it was not
possible to demonstrate differences related to visual acuity and
scotometry between the two groups.
ACKNOWLEDGEMENTS
The triamcinolone used for intravitreal injection was supplied
by “Opthalmos - Farmácia de Manipulação”, Porto Alegre, RS, Brazil
and OCT exams were performed at “Instituto de Oftalmologia
Lavinsky” - Porto Alegre (RS), Brazil.
REFERENCES
1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of
diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-74.
2. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy
Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch
Ophthalmol. 1985;103(12):1796-806.
3. Bresnick GH. Diabetic macular edema. A review. Ophthalmology. 1986;93(7):989-97.
4. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy
for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am
J Ophthalmol. 2000;130(2):178-86.
5. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone
for uveitic cystoid macular edema: an optical coherence tomography study.
Ophthalmology. 2001;108(4):765-72.
6. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide
for macular edema due to central retinal vein occlusion. Br J Ophthalmol. 2002; 86(2):247-8.
7. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of
triamcinolone acetonide. Br J Ophthalmol. 2003;87(1):24-7.
8. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal
triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004;137(4):758-60.
9. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis
following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;
136(5):791-6. Comment in Am J Ophthalmol. 2004;137(6):1158-9; author reply 1160-1. Am J
Ophthalmol. 2004;137(6):1159-60; author reply 1160-1. Am J Ophthalmol. 2004;137(6):1166;
author reply 1167. Am J Ophthalmol. 2003;136(5):918-9.
10. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse
diabetic macular edema. Arch Ophthalmol. 2003;121(1):57-61.
11. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal
triamcinolone acetonide for diffuse diabetic macular edema: 6-month results of a prospective
controlled trial. Acta Ophthalmol Scand. 2006;84(5):624-30.
12. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal
triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-7.
13. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbauemer U, Harder B. Follow-up after
intravitreal triamcinolone acetonide for diabetic macular edema. Eur J Ophthalmol. 2006;
16(4):566-72.
14. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal
triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective
controlled trial. Ophthalmology. 2004;111(2):218-24; discussion 224-5.
15. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triancinolone for
refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled,
randomized clinical trial. Ophthalmology. 2006;113(9):1533-8.
16. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone
acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124(5): 653-8.
17. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus
sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema:
six-month outcomes. Ophthalmology. 2007;114(12):2162-7.
18. Nicolò M, Nasciuti F, Lai S, Ghiglione D, Borgia L, Calabria G. Intravitreal triamcinolone
acetonide as primary treatment for diffuse diabetic macular edema: a prospective noncomparative
interventional case series. Eur J Ophthalmol. 2006;16(1):129-33.
19. Lattanzio R, Brancato R, Pierro L, Bandello F, Iaccher B, Fiore T, Maestranzi G. Macular
thickness measured by optical coherence tomography (OCT) in diabetic patients. Eur J
Ophthalmol. 2002;12(6):482-7.
20. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care.
2007;30 Suppl 1:S4-S41.
21. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR.
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6
years from diagnosis. Diabetologia. 2001;44(2):156-63.
22. Gomes MB, Gianella D, Faria M, Tambascia M, Fonseca RM, Réa R, et al. Prevalence of Type
2 diabetic patients within the targets of care guidelines in daily clinical practice: a multicenter
study in Brazil. Rev Diabet Stud. 2006;3(2):82-7.
23. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults
with previously diagnosed diabetes. JAMA. 2004;291(3):335-42.
24. Lam DS, Chan CK, Mohamed S, Lai TY, Li KK, Li PS, et al. A prospective randomised trial of
different doses of intravitreal triamcinolone for diabetic macular edema. Br J Ophthalmol.
2007;91(2):199-203.
25. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular
endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and
other retinal disorders. Am J Ophthalmol. 2002;133(4):537-43.
Arq Bras Oftalmol. 2011;74(5):343-7
347